

LITERATURA

1. Freemantle N, Cleland J, Young P, et al. beta Blockade after myocardial infarction: systematic review and meta regression analysis. *BMJ (Clinical research ed)*. 1999;318(7200):1730-7.
2. Martinez-Milla J, Raposeiras-Roubin S, Pascual-Figal DA, et al. Role of Beta-blockers in Cardiovascular Disease in 2019. *Revista espanola de cardiologia*. 2019;72(10):844-52.
3. Dahl Aarvik M, Sandven I, Dondo TB, et al. Effect of oral beta-blocker treatment on mortality in contemporary post-myocardial infarction patients: a systematic review and meta-analysis. *Eur Heart J Cardiovasc Pharmacother*. 2019;5(1):12-20.
4. Zeitouni M, Kerneis M, Lattuca B, et al. Do Patients need Lifelong beta-Blockers after an Uncomplicated Myocardial Infarction? *Am J Cardiovasc Drugs*. 2019;19(5):431-8.
5. Raposeiras-Roubin S, Abu-Assi E, Redondo-Diequez A, et al. Prognostic Benefit of Beta-blockers After Acute Coronary Syndrome With Preserved Systolic Function. Still Relevant Today? *Revista espanola de cardiologia*. 2015;68(7):585-91.
6. Dondo TB, Hall M, West RM, et al. beta-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction. *Journal of the American College of Cardiology*. 2017;69(22):2710-20.
7. Kim J, Kang D, Park H, et al. Long-term beta-blocker therapy and clinical outcomes after acute myocardial infarction in patients without heart failure: nationwide cohort study. *European heart journal*. 2020;41(37):3521-9.
8. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *European heart journal*. 2021;42(36):3599-726.
9. Watanabe H, Ozasa N, Morimoto T, et al. Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. *PLoS One*. 2018;13(8):e0199347.
10. Munkhaugen J, Ruddox V, Halvorsen S, et al. BETA-blocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point study. *American heart journal*. 2019;208:37-46.
11. Kristensen AMD, Bovin A, Zwisler AD, et al. Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction: study protocol for a randomized controlled trial. *Trials*. 2020;21(1):415.
12. Rossello X, Raposeiras-Roubin S, Latini R, et al. Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT). *Eur Heart J Cardiovasc Pharmacother*. 2022;8(3):291-301.
13. Puymirat E, Riant E, Aissaoui N, et al. beta blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study. *BMJ (Clinical research ed)*. 2016;354:i4801.
14. Mars K, Wallert J, Held C, et al. Association between beta-blocker dose and cardiovascular outcomes after myocardial infarction: insights from the SWEDEHEART registry. *Eur Heart J Acute Cardiovasc Care*. 2021;10(4):372-9.
15. Neumann A, Maura G, Weill A, et al. Clinical Events After Discontinuation of beta-Blockers in Patients Without Heart Failure Optimally Treated After Acute Myocardial Infarction: A Cohort Study on the French Healthcare Databases. *Circ Cardiovasc Qual Outcomes*. 2018;11(4):e004356.
16. Yndigeegn T, Lindahl B, Mars K, et al. Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction. *The New England journal of medicine*. 2024;390(15):1372-81.
17. Silvain J, Cayla G, Ferrari E, et al. Beta-Blocker Interruption or Continuation after Myocardial Infarction. *The New England journal of medicine*. 2024;391(14):1277-86.
18. Chi KY, Lee PL, Chowdhury I, et al. Beta-Blockers for Secondary Prevention following Myocardial Infarction in Patients Without Reduced Ejection Fraction or Heart Failure: An Updated Meta-Analysis. *European journal of preventive cardiology*. 2024.
19. Montalescot G, Giovachini L, Silvain J. Beta-Blockers After Myocardial Infarction: Returning From Injured Reserve. *European journal of preventive cardiology*. 2025.
20. Gillman MW, Kannel WB, Belanger A, et al. Influence of heart rate on mortality among persons with hypertension: the Framingham Study. *American heart journal*. 1993;125(4):1148-54.

KNIŽNÍ NOVINKA



Vnitřní lékařství 2., zcela přepracované vydání

Miroslav Souček, Bohuslav Kianička a kolektiv

Především obrovský pokrok v diagnostice a léčbě v jednotlivých podoborech vnitřního lékařství, nahromadění nových poznatků, ale také zájem lékařů o původní učebnici, která poskytuje prostor nejen integrálním oborům interní medicíny, ale i oborům, které s ní úzce souvisejí, vedl k napsání druhého vydání publikace.

Tato dvoudílná monografie je řazena do 20 kapitol, v nichž se kromě základních oborů vnitřního lékařství (kardiologie, pneumologie, gastroenterologie, nefrologie, onkologie, hematologie, revmatologie, endokrinologie a metabolismu, geriatrie) dotýká i oborů blízkých, jako jsou neurologie, psychiatrie, medicína akutních stavů, otravy, bolest, infekční nemoci, výživa, imunologie či genetika. Je zde zařazena i kapitola o zdraví a nemoci a nově kapitola zabývající se paliativní medicínou a multimorbiditou ve vnitřním lékařství, které stále více ovlivňují naši klinickou praxi.

Cena: 2 999 Kč, Stran: 1532, ISBN: 978-80-271-5142-4

[https://www.gradac.cz/vnitri-lekarstvi-\(3\)-13876/](https://www.gradac.cz/vnitri-lekarstvi-(3)-13876/)